Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2021

View Archived Issues

ROR1 TriKE candidate shows promise in preclinical models of prostate cancer

SLP76 deficiency leads to severe combined immunodeficiency in humans

FDA clears initiation of phase I study of TTAX-03 for facet joint pain in osteoarthritis

Preliminary topline data reported from phase IIb ALTISSIMO study of GB-102

JCR discontinues development of JR-031EB for epidermolysis bullosa

Sorrento and Mount Sinai to develop antibody combinations against SARS-CoV-2

Dovitinib demonstrates promising antitumor activity in preclinical model of osteosarcoma

First patient dosed in phase IIa study of MET-642 for the treatment of NASH

Surface Oncology and Merck & Co. collaborate on immune-oncology study of SRF-388

Pirtobrutinib demonstrates safety and efficacy in multiple B-cell malignancies

Hitgen discloses new IL1-7RA antagonists

Wigen Biomedicine Technology divulges KRAS mutant inhibitors

E.U. researchers patent viral compounds for synucleinopathies

Inorbit Therapeutics synthesizes FFAR1 agonists

Artios Pharma describes new POLQ inhibitors

FDA clears IND for phase II trial of Melior's tolimidone for COVID-19

At CROI, two-way street between HIV and SARS-CoV-2

Phase III trial results reported for blinatumomab in children with high-risk first-relapse B-ALL

BARDA to fund proof-of-concept studies of ibudilast for chlorine gas-induced lung damage

Initial phase I data on tri-specific COVID-19 antiviral treatment ensovibep in healthy volunteers

VBI begins phase I/II study of COVID-19 vaccine candidate VBI-2902

PI3K inhibitor umbralisib shows clinical activity in patients with indolent non-Hodgkin's lymphoma

Dosing begins in first-in-human study of CAN-106 for complement dysregulation diseases

Affimed continues REDIRECT trial of AFM-13 in PTCL after interim futility analysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...